Who we are

CCTG is a cooperative oncology group that designs and administers cancer clinical trials

The Canadian Cancer Trials Group (CCTG) is an academic cooperative oncology group that designs and conducts clinical trials testing cancer therapy, supportive care and prevention interventions across Canada. The Group is a collaborative network of researchers, physicians, scientists, statisticians and patients internationally recognized for finding the treatments that give people with cancer longer, better quality lives.

Created in 1980, the group has run trials resulting in major, life-saving breakthroughs in breast, colorectal, blood, lung, ovarian, brain and prostate cancer. The network is made of more than 85 member institutions, comprising over 2,100 Canadian investigators working with 4,400 clinical trial staff and has facilitated over 600 trials. Globally, CCTG has worked with more that 20,000 collaborators and clinical trial professionals in 40 countries on 6 continents. Most importantly are the approximately 3,000 patient volunteers per year who participate in our trials in order to potentially receive better treatments that could also benefit others in the future.

CCTG’s Central Operations and Statistics Office is located in the Cancer Research Institute at Queen’s University, with in-house faculty researchers that include clinician scientists, researchers in community health and epidemiology, and biostatisticians.

The group is proud to be one of the national programmes of the Canadian Cancer Society (CCS), the only non-American partner of the US National Clinical Trials Network and collaborators with research cooperative groups around the world. These international partnerships are central to the success of their cancer clinical trials and crucial to the advancement of the cancer research agenda in Canada.

CCTG Vision Mission Values


Find out more:

The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer

Funding announced for clinical trial that aims to improve the outcomes for patients with colorectal cancer after surgery

The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.

More >>
Dr. Elizabeth Eisenhauer by Bernard Clark

Dr. Elizabeth Eisenhauer presented with 2021 Canada Gairdner Wightman Award

Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.

More >>
Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition

Dr. Cheung and Dr. Hay receive bridge funding - CIHR Fall 2020 competition

Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received an additional $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Fall 2020 competition matching funds awarded in the spring from this program designed to capture and support ideas with the greatest potential to advance health-related knowledge in Canada. 

More >>

CIHR funding award announced for rare cancer study

Congratulations to Dr. Tricia Cottrell, a CCTG Senior Investigator, has been awarded $872,86 to support the IND227 study from the Canadian Institutes of Health Research (CIHR) Fall Project Competition.

Malignant Pleural Mesothelioma is rare and deadly form of cancer. Patients do not respond well to the current standard of care. However, there have been some positive results using immunotherapy.  Immunotherapy is a new way of treating cancer that “turns on” an individual’s anticancer immune response.

More >>